Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173318
Title: | Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor |
Author: | Sureda, Anna Chabannon, Christian Masszi, Tamás Pohlreich, David Scheid, Christof Thieblemont, Catherine Wahlin, Björn E. Sakellari, Ioanna Russell, Nigel Janikova, Andrea Dabrowska-Iwanicka, Anna Touzeau, Cyrille Esquirol, Albert Jantunen, Esa van der Werf, Steffie Bosman, Paul Boumendil, Ariane Liu, Qianying Celanovic, Marina Montoto, Silvia Dreger, Peter |
Keywords: | Limfomes Cèl·lules mare Lymphomas Stem cells |
Issue Date: | 2020 |
Publisher: | Macmillan Publishers Limited |
Abstract: | Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41409-019-0693-z |
It is part of: | Bone Marrow Transplantation, 2020, vol. 55, p. 613-622 |
URI: | http://hdl.handle.net/2445/173318 |
Related resource: | https://doi.org/10.1038/s41409-019-0693-z |
ISSN: | 0268-3369 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
694442.pdf | 856.33 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License